Achieve Life Sciences announced October 1, 2026, that Benjamin Halladay, CPA, will become its chief financial officer on October 5, succeeding Mark Oki. The company says Halladay will oversee finance as it prepares for the possible commercialization of cytisinicline, which remains an investigational drug candidate and is not approved.
When does Benjamin Halladay become CFO?
Halladay’s appointment is effective October 5, 2026. Mark Oki is stepping down from the CFO role on the same date, according to Achieve Life Sciences’ October 1 announcement.
As an Amazon Associate I earn from qualifying purchases.
Who is Benjamin Halladay?
Achieve describes Halladay as a finance executive with more than 15 years of financial management experience and public-company CFO experience in commercial pharmaceuticals and business development. The company says he was CFO of Esperion Therapeutics from November 2022 through July 2026.
In its account of his work at Esperion, Achieve says Halladay helped deleverage the company’s balance sheet, supported its acquisition of Corstasis Therapeutics and product Enbumyst, and led the finance workstream through Esperion’s sale to ARCHIMED. Achieve reported that Esperion had more than $400 million in annual revenue and that the sale had a stated maximum value of up to $1.1 billion. The company also said the upfront cash consideration represented a 58% premium to Esperion’s April 30, 2026 closing share price. These figures are from Achieve’s announcement, not independently verified here.
#1 Best Overall
- Author: Bungay Stanier, Michael.
- Publisher: Page Two
- Pages: 244
- Publication Date: 2016-02-29
- Edition: 1
Achieve says Halladay previously held positions at Pfizer, including work on Lipitor and Chantix in its Primary Care business unit, and at National Oilwell Varco. The company reports that he earned an MBA from Fordham University and a BA from Syracuse University and is an inactive Certified Public Accountant.
What will Halladay oversee at Achieve?
Achieve says Halladay will be responsible for financial strategy, accounting, investor relations, information technology and other administrative functions. The company framed the appointment around its preparation for potential commercialization of cytisinicline, highlighting Halladay’s experience with commercial pharma operations and business development.
Rank #2
CEO Andrew D. Goldberg said Halladay had helped scale a commercial pharmaceutical organization and expand its portfolio through business development within its existing capital structure. Goldberg added that the company views Halladay’s public-company CFO and large-pharma experience as relevant as it plans for possible commercialization.
What the appointment means for cytisinicline
The hire signals that Achieve is building financial and operational capacity ahead of a potential launch, not that a launch has been approved or scheduled. Cytisinicline remains under development, and Achieve’s announcement cautions that regulatory approval and timing are uncertain. Halladay said that launch discipline is established well before the first prescription and described building the financial and operating foundation for the program as a priority.
Quick Recap
Best Value
- Brand: St. Martin's Press
- Radical Candor: Fully Revised & Updated Edition: Be a Kick-Ass Boss Without Losing Your Humanity
Rank #4
- The Five Dysfunctions of a Team
- English
- hardcover
- First Edition
- gelatine plate paper
Rank #3
- Author: Lencioni, Patrick.
- Publisher: Jossey-Bass
- Pages: 184
- Publication Date: 2000-09-01
- Edition: 1
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
